Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
624K
-
Shares change
-
-167K
-
Total reported value, excl. options
-
$3.22M
-
Value change
-
-$405K
-
Put/Call ratio
-
0.16
-
Number of buys
-
7
-
Number of sells
-
-15
-
Price
-
$5.14
Significant Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q4 2019
39 filings reported holding ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share as of Q4 2019.
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 624K shares
of 41M outstanding shares and own 1.52% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (228K shares), MARSHALL WACE, LLP (114K shares), BlackRock Inc. (57.8K shares), JANE STREET GROUP, LLC (38.1K shares), MORGAN JESS S & CO INC (30.9K shares), MORGAN STANLEY (23.2K shares), PNC Financial Services Group, Inc. (21.2K shares), GEODE CAPITAL MANAGEMENT, LLC (17K shares), Rossmore Private Capital (15.1K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (13.6K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.